Loading...
Loading...
EXAS| Name | Value |
|---|---|
| Revenues | 708.7M |
| Cost of Revenue | 196.1M |
| Gross Profit | 512.6M |
| Operating Expense | 552.0M |
| Operating I/L | -39.4M |
| Other Income/Expense | 2.0M |
| Interest Income | 11.6M |
| Pretax | -37.4M |
| Income Tax Expense | 0.8M |
| Net Income/Loss | -38.2M |
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic test products, specializing in non-invasive solutions. Their flagship product, Cologuard, is a stool-based DNA screening test for colorectal cancer and pre-cancer detection. The company also offers a range of gene expression tests for breast, prostate, and colon cancers, as well as Covid-19 testing services. With a focus on enhancing the performance of their existing products and developing new fluid-based tests, Exact Sciences generates revenue through the sale of these innovative screening and diagnostic solutions.
